Prospects for the use of NK cells in immunotherapy of human cancer.
about
A New Biological Feature of Natural Killer Cells: The Recognition of Solid Tumor-Derived Cancer Stem CellsImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumCancer Stem Cells and Their Interaction with the Tumor Microenvironment in NeuroblastomaNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyNatural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approachesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectNatural killer cell regulation by microRNAs in health and diseaseThe effect of radiation on the immune response to cancersIn vivo monitoring of natural killer cell trafficking during tumor immunotherapyHigh log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapyUnderstanding of molecular mechanisms in natural killer cell therapyImproving natural killer cell cancer immunotherapyPhase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancerContrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer CellsClinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture processInnate or adaptive immunity? The example of natural killer cellsA LysM and SH3-domain containing region of the Listeria monocytogenes p60 protein stimulates accessory cells to promote activation of host NK cells.Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44.Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice - lessons for tumor immunity.Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Generation of thyroid follicular cells from pluripotent stem cells: potential for regenerative medicine.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against RhabdomyosarcomaDonor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantationNK cell-based immunotherapy for malignant diseases.Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells.Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype.The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II study.Defining early human NK cell developmental stages in primary and secondary lymphoid tissuesNatural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveOn the role of natural killer cells in neurodegenerative diseasesDok1 and Dok2 proteins regulate natural killer cell development and function.Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosisc-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
P2860
Q26744651-E3D7FFDF-3DC8-43EC-867F-48E1C574B3B5Q26765459-72380FEE-E0E1-483E-B376-0640720D157DQ26771238-CA63C3B7-2F1F-4089-8A8F-08C603EAC6B9Q26772347-13588933-B6CD-4869-8B06-BDF7E43D2CCFQ26825652-C519C58A-986B-48DA-8C9E-C1B1E409CA03Q26826830-B69A285C-9D50-4D79-880A-661A2B99E4A9Q26849448-D08ECFA5-9436-4F6C-9DE3-8A340F8D316EQ26995372-9993D318-B9BC-4818-8ED6-94A20BC4D326Q27011245-61A04A83-FB4A-4B05-B6A4-04F15B524E1CQ27334458-5B1B5A6D-A9F7-4574-80B6-B1566082A9F3Q28086976-C2D927D3-C0BD-49E2-A814-6DEFCF419A4BQ28087719-DB171BD6-3975-4A98-B0EE-683296EB4FFAQ28266580-6A41D3E7-804D-49CD-A381-A47E2DF6289BQ28550076-F324E858-6D9C-4638-A95B-99996376E955Q28743568-19B915B2-C021-4D44-8BF3-BCF81C9B26E3Q29615106-2F042314-05A2-4D95-9A1A-891F1B640EEAQ30010211-D32C4345-5287-4C5B-AEFC-2A8CC1513B98Q30554443-884292DE-21E5-4E18-93C5-B4350A72B85AQ31118586-E5273ABE-E301-4DF3-9C07-3DDC0E8473ABQ33276035-5781A405-73C1-4AD2-8E48-0E10A1044ED6Q33311287-A582F12E-27EE-45D9-B73B-773ED087B4D8Q33393451-B2BBE404-5771-4F96-ACC9-F94036B32A1CQ33474008-5019BB3C-BAA1-4EA2-AEAD-CEBA2F699995Q33672480-190788EA-2D0E-4C21-8909-750440A2F09EQ33775547-E6F2B331-677F-4CC3-977B-983B0ED94C21Q33785788-1D28E58F-C139-4C86-B00F-9929BDE7F443Q33805980-56E470E9-4DF6-4791-8807-909208A7A666Q33827433-08FE127A-2DE5-439B-A2D4-C5D73EAEA509Q33828594-18027959-4905-4B19-B002-0D9DC18C0F5BQ34057048-950D02DC-F42C-4DB0-B069-2D41E9020F58Q34068134-3CD25715-F709-448B-A807-D9CDBAA81373Q34077847-5128B9F8-093A-49EE-A373-2CDEF8807EF2Q34154688-E052318C-0753-43C2-869B-5C83B1BA14BEQ34180695-4367923D-33E7-4DD8-B59D-8BF9E674E440Q34329075-4A7C29E5-CDC5-4CE4-B4D2-2DFA66CF931DQ34332499-43AB1745-0118-41A5-BBCF-B57C60BF4B5EQ34338159-080F4011-46B4-4548-B140-A52B1C0197C7Q34344617-0DF413A6-4690-4D9D-BC54-E21D9E1B8512Q34473170-DBDA7802-0DF1-4AF4-B562-E2766717BFF5Q34551581-FF4612C1-4DD8-420A-B258-3EBBDFA8E171
P2860
Prospects for the use of NK cells in immunotherapy of human cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Prospects for the use of NK cells in immunotherapy of human cancer.
@ast
Prospects for the use of NK cells in immunotherapy of human cancer.
@en
type
label
Prospects for the use of NK cells in immunotherapy of human cancer.
@ast
Prospects for the use of NK cells in immunotherapy of human cancer.
@en
prefLabel
Prospects for the use of NK cells in immunotherapy of human cancer.
@ast
Prospects for the use of NK cells in immunotherapy of human cancer.
@en
P356
P1476
Prospects for the use of NK cells in immunotherapy of human cancer
@en
P2093
Hans-Gustaf Ljunggren
P304
P356
10.1038/NRI2073
P577
2007-05-01T00:00:00Z